[Psychotic manifestations in children. I. Associated psychoses].
D000293:Adolescent; D000367:Age Factors; D001007:Anxiety; D002188:Cannabis / Q000009:adverse effects; D002648:Child; D002657:Child Development; D002665:Child Psychiatry; D003937:Diagnosis, Differential; D004569:Electroencephalography; D004827:Epilepsy / Q000150:complications; D005260:Female; D006212:Hallucinations / Q000139:chemically induced; D006634:Histamine H1 Antagonists / Q000009:adverse effects; D006801:Humans; D006993:Hypnotics and Sedatives / Q000009:adverse effects; D008297:Male; D008620:Meprobamate / Q000009:adverse effects; D019965:Neurocognitive Disorders / Q000175:diagnosis*; D010636:Phenols / Q000009:adverse effects; D011379:Prognosis; D011605:Psychoses, Substance-Induced / Q000175:diagnosis; D011618:Psychotic Disorders / Q000175:diagnosis / Q000209:etiology; D012559:Schizophrenia / Q000139:chemically induced
D006634:Histamine H1 Antagonists; D006993:Hypnotics and Sedatives; D010636:Phenols; D008620:Meprobamate
Psychotische Manifestationen bei Kindern I. Begleitpsychosen